Jan 15, 2020 / NTS GMT
Christine Corrado - Proactive Investors Limited - Moderator
Hello, and welcome to day two here at the biotech showcase 2020 in San Francisco. I am Christine Corrado with Proactive. Joining me right now is Ralph Kern. He is the COO and Chief Medical Officer at Brainstorm Cell Therapeutics. Ralf, great to see you.
Ralph Kearney - Brainstorm Cell Therapeutics - COO and Chief Medical Officer
Thanks, Christine. Pleasure to be here.
Christine Corrado - Proactive Investors Limited - Moderator
Ralf, we talked about a year ago in this same exact place. First off just remind investors about the company.
Ralph Kearney - Brainstorm Cell Therapeutics - COO and Chief Medical Officer
Yes, we're a biotech company that's focused on developing cellular therapeutics for neurodegenerative diseases. And we have ALS program, which is in Phase 3, fully enrolled and we're going to have data in the fourth quarter of this year.
Christine Corrado - Proactive Investors Limited
Brainstorm Cell Therapeutics Inc looks forward to top-line results for its ALS Phase 3 program Transcript
Jan 15, 2020
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers